Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Enzalutamide versus abiraterone in elderly men with metastatic castration-resistant prostate cancer
ACTRN12620000463976Phase 4Completed
- Sponsor
- WEHI
- Start
- Jun 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of enzalutamide and abiraterone in metastatic castration-resistant prostate cancer (mCRPC), sponsored by WEHI. Primary endpoints: Cognitive decline incidence, Depression rate and 1 more. Started Jun 2019; status: completed.
02
Drugs
enzalutamideabiraterone
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on ACTRN12620000463976.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12620000463976.